Canadian Hemophilia Sociey & Bayer ADVANCE Canada Research Program

This program is offered in partnership with ADVANCE Canada (ADVANCE: age-related developments and co-morbidities in hemophilia) who’s Mission is as follows:

To improve the health and Quality of Life (QoL) of older Canadians living with hemophilia by underpinning our actions and recommendations in the rigour of science conducted with and for older Canadians living with hemophilia.

In order to optimize management of age-related co-morbidities in the adult hemophilia population, ADVANCE Canada will foster patient-centred research, and disseminate scientific information to assist Canadian hemophilia-treating physicians.

Eligibility

To be eligible the applicant must be a physician or Ph.D. with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization.

Interest areas and methodologies might include but are not limited to:

• musculoskeletal problems – loss of joint and muscle function and chronic pain that can impair daily activities and worsen quality of life.
• cardiovascular disease – risk factors most frequently seen in hemophilia patients include hypertension, or high blood pressure, and being overweight.
• viral infections such as HIV and hepatitis – these conditions imply treatment with antiviral drugs, which may affect patients’ kidneys and liver.
• chronic kidney disease – this condition causes hypertension. Because of hemophilia patients’ deficient blood clotting ability, it could increase their risk of a brain hemorrhage.
• chronic pain – this condition also implies treatments that could adversely affect hemophilia patients.
• cancer – chemotherapy can cause loss of white blood cells, which could worsen hemophilia patients’ tendency to bleed.

Deadline: December 10

See Full Eligibility & Application Details